Autolus Therapeutics plc (NASDAQ:AUTL) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its stake in Autolus Therapeutics plc (NASDAQ:AUTL) by 22.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 164,686 shares of the company’s stock after selling 46,961 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.06% of Autolus Therapeutics worth $573,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Renaissance Technologies LLC increased its holdings in Autolus Therapeutics by 253.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,145,056 shares of the company’s stock worth $3,985,000 after purchasing an additional 821,156 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Autolus Therapeutics by 82.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,488,986 shares of the company’s stock worth $35,020,000 after buying an additional 2,487,778 shares during the period. BNP Paribas Financial Markets raised its holdings in Autolus Therapeutics by 2,603.8% in the first quarter. BNP Paribas Financial Markets now owns 115,399 shares of the company’s stock valued at $736,000 after acquiring an additional 111,131 shares in the last quarter. Affinity Asset Advisors LLC lifted its stake in Autolus Therapeutics by 27.4% in the second quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock worth $14,964,000 after acquiring an additional 925,000 shares during the last quarter. Finally, Millennium Management LLC grew its holdings in Autolus Therapeutics by 113.7% during the 2nd quarter. Millennium Management LLC now owns 813,031 shares of the company’s stock worth $2,829,000 after acquiring an additional 432,503 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Price Performance

Shares of AUTL opened at $4.26 on Wednesday. The firm has a market capitalization of $1.13 billion, a price-to-earnings ratio of -3.55 and a beta of 2.04. The firm’s fifty day simple moving average is $3.89 and its 200-day simple moving average is $4.13. Autolus Therapeutics plc has a twelve month low of $2.21 and a twelve month high of $7.45. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.09.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Equities analysts forecast that Autolus Therapeutics plc will post -0.84 EPS for the current fiscal year.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.